EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC-ND 4.0

Impact of Metformin and Diabetes on Tumor Response to Total Neoadjuvant Therapy in Advanced Rectal Cancer: A Multicenter Retrospective Cohort Study

Sergei Bedrikovetski iD, Mahima Raju iD, Tracy Fitzsimmons iD, Ishraq Murshed iD, Timothy J Price iD, Michael Penniment, Sudarsha Selva-Nayagam, Tarik Sammour iD

Asia-Pacific Journal of Clinical Oncology · 12.01.2026

DOI: 10.1111/ajco.70076 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Asia-Pacific Journal of Clinical Oncology, online erschienen am 12.01.2026. Verfasst von Sergei Bedrikovetski und 7 weiteren Autor:innen. Beteiligte Einrichtung: Discipline of Surgery Faculty of Health and Medical Sciences Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Health Services Charitable Gifts Board (HSCGB) Early Career Research Fellowship, Cancer Council SA Beat Cancer Project Mid-Career Clinician Researcher Fellowship.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Diabetes mellitus (DM) is associated with impaired response to neoadjuvant chemoradiotherapy in rectal cancer. Metformin may enhance treatment response by improving tumor oxygenation and inhibiting cell growth and proliferation through activation of AMP‐activated protein kinase and downstream inhibition of mTOR and HIF‐1α pathways. However, the impact of DM and metformin use in patients receiving total neoadjuvant therapy (TNT) for advanced rectal cancer remains unknown.

Objective

This study evaluates the effect of DM and metformin use on overall complete response (oCR) after TNT.

Methods

This multicenter, retrospective cohort study included consecutive rectal cancer patients treated with TNT with curative intent at three South Australian hospitals between 2019 and 2025. Patients were grouped by diabetes status and metformin use. The primary outcome was the oCR rate, encompassing both clinical complete response (cCR) and pathological complete response (pCR) rates. The main secondary outcome was response at distant sites (complete M1 response).

Results

Among 244 patients who completed TNT, 44 (18.0%) were diabetic and 31 (12.7%) patients used metformin. No significant differences in response rates were observed between diabetic and nondiabetic groups: oCR (47.7%vs. 41.5%, p = 0.450), cCR (40.9% vs. 37.5%, p = 0.673), pCR (12.5% vs. 8.3%, p = 0.457), and M1 complete response (50% vs. 36.2%, p = 0.873). Similarly, no significant differences in oCR, cCR, pCR, or complete M1 response were observed between metformin users and non‐users. However, subgroup analysis of diabetic patients demonstrated that those taking metformin had a significantly higher oCR rate than those not taking metformin (58.1% vs. 23.1%, p = 0.049).

Conclusion

Diabetes and metformin use did not significantly affect tumor response rates in the overall cohort of patients with advanced rectal cancer treated with TNT. However, among diabetic patients, metformin use was associated with improved response to TNT. Given the retrospective design and limited sample size, large‐scale prospective studies are required to validate these findings.

Schlagwörter

Stichwörter der Autor:innen

clinical complete responsediabetes mellitusmetforminpathological complete responserectal cancertotal neoadjuvant therapy

Autor:innen und Institutionen

  • Discipline of Surgery Faculty of Health and Medical Sciences Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia.
  • Colorectal Unit, Department of Surgery, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
  • Department of Medical Oncology, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia.
  • Department of Radiation Oncology, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
  • Department of Medical Oncology, Royal Adelaide Hospital, Adelaide, South Australia, Australia.

ORCID-Profile: Sergei Bedrikovetski, Mahima Raju, Tracy Fitzsimmons, Ishraq Murshed, Timothy J Price, Tarik Sammour

Förderung

  • Health Services Charitable Gifts Board (HSCGB) Early Career Research Fellowship
  • Cancer Council SA Beat Cancer Project Mid-Career Clinician Researcher Fellowship

Zitieren

APA

Bedrikovetski, S., Raju, M., Fitzsimmons, T., Murshed, I., Price, T. J., Penniment, M., Selva-Nayagam, S., & Sammour, T. (2026). Impact of Metformin and Diabetes on Tumor Response to Total Neoadjuvant Therapy in Advanced Rectal Cancer: A Multicenter Retrospective Cohort Study. Asia-Pacific Journal of Clinical Oncology. https://doi.org/10.1111/ajco.70076

Vancouver

Bedrikovetski S, Raju M, Fitzsimmons T, Murshed I, Price TJ, Penniment M, et al. Impact of Metformin and Diabetes on Tumor Response to Total Neoadjuvant Therapy in Advanced Rectal Cancer: A Multicenter Retrospective Cohort Study. Asia-Pacific Journal of Clinical Oncology. 2026. doi:10.1111/ajco.70076

BibTeX
@article{Bedrikovetski2026,
  author = {Bedrikovetski, Sergei and Raju, Mahima and Fitzsimmons, Tracy and Murshed, Ishraq and Price, Timothy J and Penniment, Michael and Selva-Nayagam, Sudarsha and Sammour, Tarik},
  title = {Impact of Metformin and Diabetes on Tumor Response to Total Neoadjuvant Therapy in Advanced Rectal Cancer: A Multicenter Retrospective Cohort Study},
  journal = {Asia-Pacific Journal of Clinical Oncology},
  year = {2026},
  doi = {10.1111/ajco.70076}
}
Kostenlos starten →